Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypoxia induces DOT1L in articular cartilage to protect against osteoarthritis
Astrid De Roover, Ana Escribano Núñez, Frederique M.F. Cornelis, Chahrazad Cherifi, Leire Casas-Fraile, An Sermon, Frederic Cailotto, Rik J. Lories, Silvia Monteagudo
Astrid De Roover, Ana Escribano Núñez, Frederique M.F. Cornelis, Chahrazad Cherifi, Leire Casas-Fraile, An Sermon, Frederic Cailotto, Rik J. Lories, Silvia Monteagudo
View: Text | PDF
Research Article Aging Bone biology

Hypoxia induces DOT1L in articular cartilage to protect against osteoarthritis

  • Text
  • PDF
Abstract

Osteoarthritis is the most prevalent joint disease worldwide, and it is a leading source of pain and disability. To date, this disease lacks curative treatment, as underlying molecular mechanisms remain largely unknown. The histone methyltransferase DOT1L protects against osteoarthritis, and DOT1L-mediated H3K79 methylation is reduced in human and mouse osteoarthritic joints. Thus, restoring DOT1L function seems to be critical to preserve joint health. However, DOT1L-regulating molecules and networks remain elusive, in the joint and beyond. Here, we identified transcription factors and networks that regulate DOT1L gene expression using a potentially novel bioinformatics pipeline. Thereby, we unraveled a possibly undiscovered link between the hypoxia pathway and DOT1L. We provide evidence that hypoxia enhanced DOT1L expression and H3K79 methylation via hypoxia-inducible factor-1 α (HIF1A). Importantly, we demonstrate that DOT1L contributed to the protective effects of hypoxia in articular cartilage and osteoarthritis. Intra-articular treatment with a selective hypoxia mimetic in mice after surgical induction of osteoarthritis restored DOT1L function and stalled disease progression. Collectively, our data unravel a molecular mechanism that protects against osteoarthritis with hypoxia inducing DOT1L transcription in cartilage. Local treatment with a selective hypoxia mimetic in the joint restores DOT1L function and could be an attractive therapeutic strategy for osteoarthritis.

Authors

Astrid De Roover, Ana Escribano Núñez, Frederique M.F. Cornelis, Chahrazad Cherifi, Leire Casas-Fraile, An Sermon, Frederic Cailotto, Rik J. Lories, Silvia Monteagudo

×

Figure 1

Bioinformatics pipeline identifies transcription factors regulating the DOT1L gene.

Options: View larger image (or click on image) Download as PowerPoint
Bioinformatics pipeline identifies transcription factors regulating the ...
(A) Overview of the bioinformatics analysis flow of the human DOT1L proximal promoter. The top part of A displays the DOT1L gene promoter region that was used for the analysis, namely –1000 bp to +100 bp relative to the transcription start site (TSS). The bottom part shows the 4 different bioinformatics web-based tools that were used and the transcription factor (TF) selection pipeline. (B) Venn diagram of the 276 TFs found by the 4 different tools, of which the TFs predicted by at least 2 different tools were selected for further analysis. (C) Overview of hits remaining after the specificity analysis. Two different approaches were used to determine whether the TFs were more specific for the DOT1L promoter compared with the aggrecan (ACAN), collagen 2a1 (COL2A1), and actin (ACTB) promoters. The diagram shows the 18 resulting TFs predicted to be more specific for DOT1L after exclusion of TFs by approach 1 or 2 as well as their overlap.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts